Petrographic and trace element characterisation of diagenetic carbonates associated with Pb-Zn sulfide and fluorite mineralisation (Upper Triassic;  Lombardy Basin;  Northern Italy)

Niccolò Coccia

doi:10.1180/mgm.2025.10124

primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma

2026-07-21

0

PRE

AI

A

Alexander CJ van Akkooi *

M

Michal Kiciński

A

Anne-Sophie Govaerts

A

Axel Hauschild

P

Piotr Rutkowski

P

Petr Arenberger

P

Paolo A. Ascierto

P

PandhaHardev (Piotr Tomczak)

G

Gaëlle Quereux

F

Federica De Galitiis

C

Caroline Dutriaux

C

Christoffer Gebhardt

E

Ellen Kapiteijn

L

L. Machet

M

Miguel GA Berciano

M

Michele Del Vecchio

M

Mathilde Jalving

T

Thomas Jouary

I

Ivana Krajsová

DOI：10.1016/j.ejca.2026.116951

Original

Original request for help

Save

Abstract

En 中文

• First and only randomized adjuvant trial combined BRAF & MEK inhibition for stage II melanoma. • Toxicity profile was consistent and manageable for encorafenib and binimetinib. • Encouraging efficacy was seen in stage II BRAF V600E/K mutant melanoma.

Keywords:

Melanoma

BRAF

Adjuvant

Encorafenib

Binimetinib

MEK

Stage II Melanoma

primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma

Abstract

Journal

Organization